Literature DB >> 9573547

Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat.

M Kushiro1, K Shikata, H Sugimoto, Y Shikata, N Miyatake, J Wada, M Miyasaka, H Makino.   

Abstract

Prostacyclin (PGI2) is known to have a relaxative action on vascular smooth muscle, an inhibitory action against platelet activation and neutrophil function. Previous studies showed the preventive effects of PGI2 on lupus nephritis and Thy-1 nephritis, although the mechanism has not been clarified. Glomerular endothelial expression of intercellular adhesion molecule-1 (ICAM-1) is up-regulated in experimental and human glomerular diseases, and is known to facilitate leukocyte infiltration into the glomeruli, which ultimately induces the various glomerular injuries. In the present study, we evaluated the therapeutic effects of PGI2 on a rat model for crescentic glomerulonephritis and investigated its putative mechanism in relation to ICAM-1-mediated leukocyte recruitment. Wistar-Kyoto (WKY) rats were injected with nephrotoxic serum and received continuous intraperitoneal infusion of PGI2. PGI2 dramatically decreased proteinuria (123.0 +/- 18.8 vs. 31.6 +/- 4.5), crescent formation and deposition of fibrinogen in the glomeruli, while the deposition of rabbit IgG, rat IgG and rat C3 along the capillary walls was not changed. Furthermore, intraglomerular expression of ICAM-1 and infiltration of macrophages were significantly suppressed by administration with PGI2. In contrast, influx of CD4 or CD8 positive cells was not altered. The present results suggest that PGI2 shows the preventive effects on experimental crescentic glomerulonephritis by inhibiting intraglomerular coagulation and ICAM-1-mediated macrophage-glomerular endothelial cell adhesive pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573547     DOI: 10.1046/j.1523-1755.1998.00881.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Therapeutics in renal disease: the road ahead for antiproliferative targets.

Authors:  Peter J Nelson; Stuart J Shankland
Journal:  Nephron Exp Nephrol       Date:  2005-12-07

2.  A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.

Authors:  Hidetomo Nakamoto; Toshiro Fujita; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2014-09-19       Impact factor: 2.388

3.  Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.

Authors:  Akio Koyama; Toshiro Fujita; Fumitake Gejyo; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2015-10-16       Impact factor: 2.388

4.  A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease.

Authors:  M Takenaka; A Iio; R Sato; T Sakamoto; H Kurumatani
Journal:  J Vet Intern Med       Date:  2017-11-13       Impact factor: 3.333

5.  The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats.

Authors:  Nahoko Sato; Masayuki Kaneko; Mitsutaka Tamura; Hajimu Kurumatani
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

6.  Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study.

Authors:  Hajimu Kurumatani; Kiyonobu Okada; Hideki Origasa; Toshiro Fujita; Masanao Isono; Hidetomo Nakamoto
Journal:  Ther Apher Dial       Date:  2021-02-21       Impact factor: 1.762

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.